18 June, 2026
The global scientific community received a significant update today with the release of Clarivate’s 2026 Journal Citation Reports (JCR). For researchers, clinicians, and policymakers in the field of pulmonary medicine, this annual data release serves as a critical barometer for the influence and reach of academic literature. Among the highlights of this year’s report is the sustained and impressive performance of the European Respiratory Society (ERS) journal portfolio, which has demonstrated marked growth across its flagship and specialist publications.
As the dissemination of high-quality, peer-reviewed respiratory research becomes increasingly vital in the face of evolving global health challenges, these metrics provide more than just a numerical score; they reflect the collective dedication of the international respiratory community.
The Core Data: ERS Publications at a Glance
The 2026 JCR data reaffirms the position of the European Respiratory Society as a premier publisher in the field of lung health. The flagship title, the European Respiratory Journal (ERJ), has once again cemented its status as a top-tier publication, securing the number two spot in the highly competitive "Respiratory System" category. With a robust Impact Factor of 23.8, the ERJ continues to set the benchmark for clinical trials, groundbreaking pathophysiology studies, and transformative reviews.
However, the strength of the ERS portfolio extends well beyond its flagship journal. The society’s commitment to providing a spectrum of dissemination platforms is evidenced by the rising metrics of its specialist titles:
- European Respiratory Review (ERR): Building on its reputation for high-level synthesis and expert commentary, the ERR saw its Impact Factor climb to 10.8.
- ERJ Open Research: This open-access title, dedicated to facilitating the rapid dissemination of scientific advances, reached an Impact Factor of 4.4, reflecting its growing role in the open-science movement.
- Breathe: The society’s clinical and educational journal, Breathe, achieved an Impact Factor of 4.5, underscoring its utility as a primary resource for medical professionals and trainees worldwide.
A Chronological Perspective: Tracking the Trajectory
The journey of the ERS journals to these current metrics is not an overnight success story, but the result of a multi-year strategic vision. To understand the significance of the 2026 figures, it is necessary to contextualize them within the broader history of the society’s publishing program.
The Foundation Years
In the early 2000s, the ERS recognized that as the complexity of respiratory disease increased—ranging from chronic obstructive pulmonary disease (COPD) to rare interstitial lung diseases—a singular journal would eventually be insufficient to capture the breadth of the field. The expansion of the portfolio began with the launch of the European Respiratory Review, designed to provide the “big picture” that clinicians needed to stay updated in a rapidly fragmenting field.
The Digital Pivot
By the mid-2010s, the emergence of open access as a dominant publishing model necessitated a shift. The introduction of ERJ Open Research was a proactive response to the needs of researchers who required faster publication cycles and broader accessibility. The steady rise of this journal, now firmly established with a 4.4 Impact Factor, serves as a testament to the success of that transition.
The Era of Influence
Over the past five years, the ERS has invested heavily in digital infrastructure, rigorous peer-review standards, and the promotion of early-career investigators. This long-term investment is what has allowed the ERJ to maintain its top-tier status while simultaneously elevating the reach of its sibling journals. Today, the 2026 metrics represent a high-water mark for the society, marking a period of unprecedented stability and growth despite the volatile landscape of global academic publishing.
Supporting Data and Industry Context
The Impact Factor, while often debated, remains the industry standard for measuring the frequency with which the "average article" in a journal has been cited in a particular year. In the "Respiratory System" category, competition is fierce, with major international societies and private publishers vying for top-tier content.
Comparative Analysis
When analyzing the 23.8 Impact Factor of the ERJ, it is important to consider the citation density of the field. Respiratory medicine has seen a surge in research volume, particularly in the post-pandemic era. The ERJ’s ability to remain at the number two position suggests a high "stickiness" of its content—meaning that authors are not only citing the journal frequently but are doing so for seminal work that influences clinical guidelines and therapeutic developments.
The Growth of Open Access
The upward trajectory of ERJ Open Research (4.4) is particularly illustrative of broader industry trends. As funding bodies—such as the European Research Council and the NIH—increasingly mandate open access for funded research, journals that offer a hybrid or fully open-access pathway are experiencing higher visibility. The ERS has strategically positioned its open-access offerings to complement, rather than cannibalize, the flagship journal, creating a holistic ecosystem for authors at different stages of their research projects.
Official Responses and Acknowledgments
Following the release of the 2026 data, leadership within the European Respiratory Society expressed profound gratitude to the stakeholders who make these metrics possible.
In a formal statement, the ERS editorial board noted:
"These figures are a reflection of the global respiratory community. The Impact Factor is not merely a number; it is a proxy for the collective trust that authors place in our journals when they choose to submit their life’s work. We extend our deepest thanks to our authors, who provide the content; our reviewers, who provide the critical gatekeeping necessary for scientific integrity; and our editors, who curate the high-quality science that defines the ERS brand."
The sentiment across the editorial offices is one of humility balanced with ambition. The society has emphasized that while these numbers are encouraging, the true goal remains the improvement of patient outcomes. "If our journals can inform a clinician in a remote setting about a new therapeutic approach, or provide a researcher with the data they need to build their next study, then we have succeeded," a senior editor remarked during the internal review of the JCR data.
Implications: What This Means for the Future of Respiratory Research
The 2026 Impact Factor release has profound implications for the future of respiratory medicine and the publishing landscape.
1. The Power of Specialized Literature
The growth of Breathe to a 4.5 Impact Factor highlights a crucial trend: the appetite for educational and clinically focused content. In an era where information overload is a significant challenge for healthcare providers, journals that offer concise, expert-vetted, and practical information are becoming increasingly influential.
2. Maintaining Editorial Integrity
As ERS journals continue to climb in influence, the pressure to maintain rigorous peer review increases. The society has indicated that it will continue to leverage advanced digital tools to expedite the review process without compromising the quality of feedback. This commitment to "speed with rigor" is expected to remain a core pillar of their strategy heading into 2027.
3. Strengthening the Global Pipeline
For young investigators, the visibility provided by the ERS journal portfolio is a career-defining asset. The high Impact Factors of the current portfolio mean that research published within these pages is more likely to be cited by global health organizations, regulatory bodies, and international guideline committees. This creates a virtuous cycle where high-quality research is rewarded with high visibility, attracting even more high-quality submissions.
4. Navigating the Open Science Future
The success of ERJ Open Research suggests that the ERS is well-positioned to navigate the ongoing transition toward a fully open-science publishing model. As the industry moves away from traditional subscription-based models, the society’s ability to maintain financial sustainability while growing its reach will be the benchmark by which other medical societies measure their own digital transformations.
Conclusion: Looking Ahead
The 2026 Journal Citation Reports serve as a powerful validation of the ERS’s mission. By balancing the prestige of a flagship journal with the accessibility of open-access platforms and the utility of clinical-education titles, the society has created a robust and responsive publishing ecosystem.
As the medical field looks toward the remainder of the decade, the focus for the European Respiratory Society remains clear: to continue providing a platform for the world’s most impactful respiratory science, fostering a community that is as global as the diseases it seeks to treat. Whether through original research, systematic reviews, or educational narratives, the ERS publications are poised to remain at the forefront of the global conversation on lung health.
For those interested in contributing to this ongoing legacy of scientific excellence, the ERS invites researchers from across the globe to submit their work, ensuring that the next generation of breakthroughs finds a home in one of the most respected journal portfolios in medicine.
For further information on submission guidelines and to view the latest research, please visit the official ERS publications portal.
